The new fund extends Sofinnova’s 20-year track record of company creation with capacity to launch six to eight new ventures across Europe and the US PARIS, France – September 28, 2026 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of […]
Approval is based on NEXUS data and follows positive CHMP opinion in July; first European launch is expected by end of 2026 Barcelona, Spain and Düsseldorf, Germany – 25 September, 2026 – Neuraxpharm Group and Minoryx Therapeutics, today announce that the European Commission (EC) has granted marketing authorisation under exceptional circumstances for NEZGLYAL® (leriglitazone), an […]
Lund, Sweden, September 24, 2026. Hansa Biopharma AB (publ), “Hansa” (Nasdaq Stockholm: HNSA), announced today the election of Shannon Campbell and Gregory Perry to Hansa’s Board of Directors, effective September 22, 2026 until the end of the next Annual General Meeting. Read more…
Positive interim review marks key milestone for POLB 001 clinical development 24 September 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the ongoing TOPICAL clinical trial will proceed as planned following a positive review of data from […]
Stockholm, Sweden, September 24, 2026 – BOOST Pharma (“BOOST” or “the Company”), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases, today announced that it has been selected as a 2026 Innovation Spotlight company at the upcoming Cell & Gene Meeting on the Mesa, taking place in Phoenix, […]
